BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...those acquired via its purchase of Scotland-based Synpromics Ltd....
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...BD, and Steve Nardi as VP of manufacturing and engineering operations. Meeks was VP of BD at Synpromics Ltd....
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...things like vectorized antibodies.” AskBio added synthetic promoter technology to its toolkit when it acquired Synpromics...
BioCentury | Aug 13, 2019
Company News

Via Synpromics takeout, AskBio adds promoters to gene therapy platform

...With the acquisition of Synpromics, well-funded gene therapy developer AskBio has added synthetic promoter technology to...
...on programs sold off to biopharmas (see "AskBio Answers Investors' Call" ). The acquisition of Synpromics Ltd....
..."Synthetic Expressions" ). AskBio CEO Sheila Mikhail told BioCentury the company has been working with Synpromics...
BioCentury | Oct 18, 2018
Preclinical News

Flurry of news highlights latest in switch-controlled gene therapy

...series of company announcements signal advances in switch-controlled gene therapy. uniQure N.V. (NASDAQ:QURE) and partner Synpromics Ltd....
...to Synpromics, the data show that a short and highly selective liver promoter developed by Synpromics...
...synthetic promoters with liver cell-specific activity small enough for optimized delivery via adeno-associated virus (AAV). Synpromics...
BioCentury | Jan 26, 2018
Company News

Synpromics, UCL partner to develop tissue-specific promoters

...synthetic tissue-specific promoters for use in specialized immune cells, including lymphoid, myeloid and microglia cells. Synpromics...
...to deliver a therapeutic protein. Synpromics said the collaborators will initially target chronic granulomatous disorder. Synpromics...
...in time for publication. Synpromics Ltd., Edinburgh, U.K. University College London, London, U.K. Business: Hematology Jaime De Leon Synpromics Ltd. University...
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

...promoters, and co-opting CRISPR machinery or pharmacological DNA binders to generate transcription factors. Synthetic promoters. Synpromics Ltd....
...natural sequences that guide cell type-specific gene expression,” said Michael Roberts, founder and CSO of Synpromics Ltd....
...at the stage where we’re building synthetic promoters in a more rational fashion.” Michael Roberts, Synpromics...
BioCentury | Dec 1, 2017
Company News

Synpromics, UCL to develop gene therapy for PD

...London to generate synthetic CNS gene promoters and develop a gene therapy for Parkinson's disease. Synpromics...
...select optimal gene switches for UCL to develop gene therapy vectors to treat young-onset PD. Synpromics...
...22 ). Synpromics Ltd., Edinburgh, U.K. University College London, London, U.K. Business: Neurology Elizabeth S. Eaton Solid Biosciences LLC Synpromics Ltd. University...
BioCentury | Nov 28, 2017
Company News

Synpromics, UCL to develop gene therapy for PD

...PD. Details were not disclosed. Synpromics did not respond to inquiries in time for publication. Synpromics...
...therapies for Duchenne muscular dystrophy (DMD) (see BioCentury Extra, Sept. 20) . Elizabeth S. Eaton Solid Biosciences LLC Synpromics Ltd. University...
BioCentury | Sep 22, 2017
Company News

Synpromics, Solid targeting DMD with transcription promoters

...Solid Biosciences LLC (Cambridge, Mass.) access to muscle-selective synthetic DNA transcription promoter candidates based on Synpromics'...
...declined to provide terms of the deal, but Solid spokesperson Courtney Heath told BioCentury that "Synpromics'...
...candidates identified under the deal will not be applied to Solid's existing candidates, including SGT-001. Synpromics Ltd....
Items per page:
1 - 10 of 15
BioCentury | Oct 26, 2020
Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...those acquired via its purchase of Scotland-based Synpromics Ltd....
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...BD, and Steve Nardi as VP of manufacturing and engineering operations. Meeks was VP of BD at Synpromics Ltd....
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...things like vectorized antibodies.” AskBio added synthetic promoter technology to its toolkit when it acquired Synpromics...
BioCentury | Aug 13, 2019
Company News

Via Synpromics takeout, AskBio adds promoters to gene therapy platform

...With the acquisition of Synpromics, well-funded gene therapy developer AskBio has added synthetic promoter technology to...
...on programs sold off to biopharmas (see "AskBio Answers Investors' Call" ). The acquisition of Synpromics Ltd....
..."Synthetic Expressions" ). AskBio CEO Sheila Mikhail told BioCentury the company has been working with Synpromics...
BioCentury | Oct 18, 2018
Preclinical News

Flurry of news highlights latest in switch-controlled gene therapy

...series of company announcements signal advances in switch-controlled gene therapy. uniQure N.V. (NASDAQ:QURE) and partner Synpromics Ltd....
...to Synpromics, the data show that a short and highly selective liver promoter developed by Synpromics...
...synthetic promoters with liver cell-specific activity small enough for optimized delivery via adeno-associated virus (AAV). Synpromics...
BioCentury | Jan 26, 2018
Company News

Synpromics, UCL partner to develop tissue-specific promoters

...synthetic tissue-specific promoters for use in specialized immune cells, including lymphoid, myeloid and microglia cells. Synpromics...
...to deliver a therapeutic protein. Synpromics said the collaborators will initially target chronic granulomatous disorder. Synpromics...
...in time for publication. Synpromics Ltd., Edinburgh, U.K. University College London, London, U.K. Business: Hematology Jaime De Leon Synpromics Ltd. University...
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

...promoters, and co-opting CRISPR machinery or pharmacological DNA binders to generate transcription factors. Synthetic promoters. Synpromics Ltd....
...natural sequences that guide cell type-specific gene expression,” said Michael Roberts, founder and CSO of Synpromics Ltd....
...at the stage where we’re building synthetic promoters in a more rational fashion.” Michael Roberts, Synpromics...
BioCentury | Dec 1, 2017
Company News

Synpromics, UCL to develop gene therapy for PD

...London to generate synthetic CNS gene promoters and develop a gene therapy for Parkinson's disease. Synpromics...
...select optimal gene switches for UCL to develop gene therapy vectors to treat young-onset PD. Synpromics...
...22 ). Synpromics Ltd., Edinburgh, U.K. University College London, London, U.K. Business: Neurology Elizabeth S. Eaton Solid Biosciences LLC Synpromics Ltd. University...
BioCentury | Nov 28, 2017
Company News

Synpromics, UCL to develop gene therapy for PD

...PD. Details were not disclosed. Synpromics did not respond to inquiries in time for publication. Synpromics...
...therapies for Duchenne muscular dystrophy (DMD) (see BioCentury Extra, Sept. 20) . Elizabeth S. Eaton Solid Biosciences LLC Synpromics Ltd. University...
BioCentury | Sep 22, 2017
Company News

Synpromics, Solid targeting DMD with transcription promoters

...Solid Biosciences LLC (Cambridge, Mass.) access to muscle-selective synthetic DNA transcription promoter candidates based on Synpromics'...
...declined to provide terms of the deal, but Solid spokesperson Courtney Heath told BioCentury that "Synpromics'...
...candidates identified under the deal will not be applied to Solid's existing candidates, including SGT-001. Synpromics Ltd....
Items per page:
1 - 10 of 15